Ventyx Biosciences, Inc.
7.37-0.01 (-0.14%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · VTYX · USD
Key Stats
Market Cap
525.54MP/E (TTM)
-Basic EPS (TTM)
-1.66Dividend Yield
0%Recent Filings
8-K
Positive VTX3232 Phase 2 results
Ventyx Biosciences unveiled positive Phase 2 topline results for VTX3232, its oral NLRP3 inhibitor, on October 22, 2025, showing rapid 78% reductions in hsCRP at week 12 versus placebo's 3% increase in obese patients with cardiovascular risks. The drug also cut IL-6 below the 1.65 ng/L CV risk threshold, lowered Lp(a) and liver inflammation, and proved safe with adverse events matching placebo. VTX3232 adds inflammation control to semaglutide without boosting weight loss. It targets residual inflammatory risk in millions of CV patients.
10-Q
Q2 FY2025 results
Ventyx Biosciences narrowed its Q2 net loss to $27.0M from $32.0M a year earlier, as R&D expenses dropped 20% y/y to $22.3M amid wind-downs for tamuzimod and VTX958, while VTX3232 and VTX2735 programs ramped up for Parkinson's and pericarditis trials. Operating loss improved 18% y/y to $29.3M, with diluted EPS at -$0.38 versus -$0.45 last year, confirmed against 71.2M weighted shares. Cash and marketable securities stood at $209.0M at quarter-end, down from $217.3M year-start but sufficient for at least 12 months of runway; no debt or M&A noted. Free cash flow not disclosed in the 10-Q. Yet competition from Novartis and Roche in NLRP3 inhibitors looms large.
8-K
Ventyx Q2 results spotlight Parkinson's progress
Ventyx Biosciences reported Q2 2025 financials, highlighting positive Phase 2a data for VTX3232 in early Parkinson's, showing safety, high CSF exposure, and biomarker reductions that improved symptoms. The company holds $209.0 million in cash, funding operations into H2 2026, while advancing VTX2735 in recurrent pericarditis and VTX3232 in cardiometabolic diseases, with topline results due Q4 2025. Net loss narrowed to $27.0 million from $32.0 million year-over-year. R&D costs dropped amid pipeline momentum.
8-K
Positive VTX3232 Parkinson's data
Ventyx Biosciences unveiled positive top-line results from its Phase 2a trial of VTX3232, a CNS-penetrant NLRP3 inhibitor, in ten patients with early-stage Parkinson's disease on June 17, 2025. The 28-day, open-label study confirmed safety with no drug-related adverse events, robust CSF and plasma exposures exceeding IC90 for 24 hours, and reductions in NLRP3 biomarkers like IL-1b and IL-18. VTX3232 also improved motor and non-motor symptoms per MDS-UPDRS scores. Yet, as a small open-label trial, results may not predict larger studies.
8-K
Annual meeting results disclosed
Ventyx Biosciences held its annual stockholder meeting on June 4, 2025, with 70% of shares represented. Shareholders re-elected directors Somasundaram Subramaniam and Sheila Gujrathi to Class I seats until 2028, despite Subramaniam receiving more withheld votes than support. The say-on-pay proposal passed with 20.4 million for versus 10.9 million against. Ernst & Young LLP's appointment as auditor for 2025 was ratified overwhelmingly. Strong turnout signals investor confidence, yet director vote splits highlight governance scrutiny.
ANNX
Annexon, Inc.
3.19-0.26
BLRX
BioLineRx Ltd.
3.50-0.18
FBRX
Forte Biosciences, Inc.
14.38+0.92
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
IVBXF
Innovent Biologics Inc.
11.14-0.56
TYRA
Tyra Biosciences, Inc.
15.24+0.68
VERA
Vera Therapeutics, Inc.
29.36-0.60
VINC
Vincerx Pharma, Inc.
0.03+0.00
VKTX
Viking Therapeutics, Inc.
35.22+0.29
VRTX
Vertex Pharmaceuticals Incorpor
417.21-5.18